A Phase 1b Open-Label Study of DISC-3405 in Participants With Sickle Cell Disease (SCD)
Phase 1
24
about 1.8 years
18+
3 sites in AL, IN, NY
About this study
Researchers are testing a new treatment called DISC-3405 for people with sickle cell disease. The trial will evaluate the safety, tolerability, and how the drug works in the body at different doses.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take DISC-3405
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Primary: Safety and tolerability of DISC-3405 administration in participants with SCD
Secondary: Apparent clearance (CL/F) following the first dose, Area under the plasma concentration versus time curve extrapolated to infinity (AUC∞) following the first dose, Elimination half-life (T1/2el) following the first dose, Maximum plasma concentration (Cmax) following the first dose, Pharmacodynamic (PD) properties of DISC-3405 in participants with SCD by change from baseline for Lactate Dehydrogenase (LDH), Pharmacodynamic (PD) properties of DISC-3405 in participants with SCD by change from baseline for Red Blood Cell Count (RBC), Pharmacodynamic (PD) properties of DISC-3405 in participants with SCD by change from baseline for bilirubin (direct and indirect), Pharmacodynamic (PD) properties of DISC-3405 in participants with SCD by change from baseline for hematocrit (HCT)